Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amarin Corporation Plc (AMRN)
NASDAQ:AMRN
Holding AMRN?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.05Last Year’s EPS
-$0.01Same Quarter Last Year
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 30, 2024
|% Change Since: -23.88%
|Next Earnings Date:Feb 26, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted the potential for growth in Europe and other global markets but was overshadowed by significant declines in U.S. revenue and gross margins, increased net loss, and ongoing pricing pressures due to generic competition.Company Guidance
During the Q3 2024 earnings call for Amarin Corporation, executives provided guidance emphasizing the significant growth potential for VASCEPA and VAZKEPA, particularly in European markets where they have recently been granted intellectual property protection until 2039. The company reported total net revenue of $42.3 million, with U.S. product revenue at $30.6 million, reflecting a decline due to increased generic competition. However, European net product revenue increased to $4.3 million, driven by growth in Spain and the U.K. Amarin's strategic focus is on expanding market access and reimbursement processes in Europe and other global markets, where they have launched in 8 European countries, representing about half of the market opportunity. The executives highlighted their commitment to leveraging over 300 scientific publications and support from 50 medical societies to drive the product's adoption and maximize its value in addressing cardiovascular risk worldwide.Expansion in European Markets
VASCEPA has launched in 8 European countries with pricing and reimbursement secured in Greece and Portugal. The IP has been extended to 2039, indicating a long runway for growth.
Growth in Europe and Rest of World Markets
European net product revenue increased by $3.5 million compared to the prior year and $800,000 compared to the previous quarter. Rest of the world partnerships are starting to gain momentum, with Australia and China recently beginning commercialization.
Significant Global Unmet Need for Cardiovascular Risk Reduction
VASCEPA and VAZKEPA address a global unmet need in cardiovascular risk reduction, supported by more than 300 publications and recognition from over 50 medical societies worldwide.
---
AMRN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AMRN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 30, 2024 | $0.60 | $0.58 | -3.33% |
| Jul 31, 2024 | $0.78 | $0.68 | -12.82% |
| May 01, 2024 | $0.92 | $0.84 | -8.70% |
| Feb 29, 2024 | $1.32 | $1.07 | -18.94% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Amarin Corporation Plc (AMRN) report earnings?
Amarin Corporation Plc (AMRN) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is Amarin Corporation Plc (AMRN) earnings time?
Amarin Corporation Plc (AMRN) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AMRN EPS forecast?
AMRN EPS forecast for the fiscal quarter 2024 (Q4) is -$0.05.
---